[
  {
    "source_file_section": "TITLE",
    "source_heading_number": "",
    "parent_heading_num_seq": [
      ""
    ],
    "parent_sec_id_seq": [
      1
    ],
    "derived_heading_level": 1,
    "pt_from_ontology": [
      ""
    ],
    "medical_terms": [],
    "page": 1,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "2_section_metadata",
    "sec_id": 1,
    "child_secid_seq": [
      [
        1,
        "",
        "TITLE",
        1
      ]
    ]
  },
  {
    "source_file_section": "TABLEOF CONTENTS",
    "source_heading_number": "Table",
    "parent_heading_num_seq": [
      "Table"
    ],
    "parent_sec_id_seq": [
      2
    ],
    "derived_heading_level": 1,
    "pt_from_ontology": [
      ""
    ],
    "medical_terms": [],
    "page": 0,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "2_section_metadata",
    "sec_id": 2,
    "child_secid_seq": [
      [
        2,
        "Table",
        "TABLEOF CONTENTS",
        1
      ]
    ]
  },
  {
    "source_file_section": "LIST OF ABBREVIATIONS",
    "source_heading_number": "",
    "parent_heading_num_seq": [
      ""
    ],
    "parent_sec_id_seq": [
      3
    ],
    "derived_heading_level": 1,
    "pt_from_ontology": [
      ""
    ],
    "medical_terms": [],
    "page": 1,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "2_section_metadata",
    "sec_id": 3,
    "child_secid_seq": [
      [
        3,
        "",
        "LIST OF ABBREVIATIONS",
        1
      ]
    ]
  },
  {
    "source_file_section": "INTRODUCTION",
    "source_heading_number": "1",
    "parent_heading_num_seq": [
      "1"
    ],
    "parent_sec_id_seq": [
      4
    ],
    "derived_heading_level": 1,
    "pt_from_ontology": [
      ""
    ],
    "medical_terms": [],
    "page": 4,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "2_section_metadata",
    "sec_id": 4,
    "child_secid_seq": [
      [
        4,
        "1",
        "INTRODUCTION",
        1
      ],
      [
        5,
        "1.1",
        "Disease Background",
        2
      ],
      [
        6,
        "1.2",
        "Nirsevimab Background",
        2
      ],
      [
        7,
        "1.3",
        "Summary of Nonclinical Experience",
        2
      ],
      [
        8,
        "1.4",
        "Summary of Clinical Experience",
        2
      ],
      [
        9,
        "1.4.1",
        "Phase 1a Study D5290C00001",
        3
      ],
      [
        10,
        "1.4.2",
        "Phase 1b/2a Study D5290C00002",
        3
      ],
      [
        11,
        "1.4.3",
        "Phase 2b Study D5290C00003",
        3
      ],
      [
        12,
        "1.5",
        "Rationale for Conducting the Study",
        2
      ],
      [
        13,
        "1.6",
        "Benefit-Risk and Ethical Assessment",
        2
      ],
      [
        14,
        "1.7",
        "Research Hypotheses",
        2
      ],
      [
        15,
        "1.7.1",
        "Primary Hypothesis",
        3
      ],
      [
        16,
        "1.7.2",
        "Secondary Hypotheses",
        3
      ]
    ]
  },
  {
    "source_file_section": "OBJECTIVES AND ENDPOINTS",
    "source_heading_number": "2",
    "parent_heading_num_seq": [
      "2"
    ],
    "parent_sec_id_seq": [
      17
    ],
    "derived_heading_level": 1,
    "pt_from_ontology": [
      ""
    ],
    "medical_terms": [],
    "page": 9,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "2_section_metadata",
    "sec_id": 17,
    "child_secid_seq": [
      [
        17,
        "2",
        "OBJECTIVES AND ENDPOINTS",
        1
      ],
      [
        18,
        "Table 1",
        "Primary Objective and Associated Endpoint",
        "2"
      ],
      [
        19,
        "Table 2",
        "Secondary Objectives and Associated Endpoints",
        "2"
      ],
      [
        20,
        "Table 3",
        "Exploratory Objectives and Associated Endpoints",
        "2"
      ]
    ]
  },
  {
    "source_file_section": "STUDY DESIGN",
    "source_heading_number": "3",
    "parent_heading_num_seq": [
      "3"
    ],
    "parent_sec_id_seq": [
      21
    ],
    "derived_heading_level": 1,
    "pt_from_ontology": [
      ""
    ],
    "medical_terms": [],
    "page": 0,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "2_section_metadata",
    "sec_id": 21,
    "child_secid_seq": [
      [
        21,
        "3",
        "STUDY DESIGN",
        1
      ],
      [
        22,
        "3.1",
        "Description of the Study",
        2
      ],
      [
        23,
        "3.1.1",
        "Overview",
        3
      ]
    ]
  },
  {
    "source_file_section": "Figure 1  Study Flow Diagram",
    "source_heading_number": "",
    "parent_heading_num_seq": [
      ""
    ],
    "parent_sec_id_seq": [
      24
    ],
    "derived_heading_level": 1,
    "pt_from_ontology": [
      ""
    ],
    "medical_terms": [],
    "page": 4,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "2_section_metadata",
    "sec_id": 24,
    "child_secid_seq": [
      [
        24,
        "",
        "Figure 1  Study Flow Diagram",
        1
      ],
      [
        25,
        "3.1.2",
        "Treatment Regimen",
        3
      ],
      [
        26,
        "3.2",
        "Rationale for Dose, Population, and Endpoints",
        2
      ],
      [
        27,
        "3.2.1",
        "Dose Rationale",
        3
      ],
      [
        28,
        "3.2.2",
        "Rationale for Study Population",
        3
      ],
      [
        29,
        "3.2.3",
        "Rationale for Endpoints",
        3
      ]
    ]
  },
  {
    "source_file_section": "MATERIALS AND METHODS",
    "source_heading_number": "4",
    "parent_heading_num_seq": [
      "4"
    ],
    "parent_sec_id_seq": [
      30
    ],
    "derived_heading_level": 1,
    "pt_from_ontology": [
      ""
    ],
    "medical_terms": [],
    "page": 5,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "2_section_metadata",
    "sec_id": 30,
    "child_secid_seq": [
      [
        30,
        "4",
        "MATERIALS AND METHODS",
        1
      ],
      [
        31,
        "4.1",
        "Subjects",
        2
      ],
      [
        32,
        "4.1.1",
        "Number of Subjects",
        3
      ],
      [
        33,
        "4.1.2",
        "Inclusion Criteria",
        3
      ],
      [
        34,
        "4.1.3",
        "Exclusion Criteria",
        3
      ],
      [
        35,
        "4.1.4",
        "Subject Enrollment and Randomization",
        3
      ],
      [
        36,
        "4.1.5",
        "Withdrawal from the Study",
        3
      ],
      [
        37,
        "4.1.6",
        "Discontinuation of Investigational Product",
        3
      ],
      [
        38,
        "4.1.7",
        "Lost to Follow-up",
        3
      ],
      [
        39,
        "4.1.8",
        "Replacement of Subjects",
        3
      ],
      [
        40,
        "4.1.9",
        "Withdrawal of Informed Consent for Data and Biological Samples",
        3
      ],
      [
        41,
        "4.2",
        "Schedule of Study Procedures",
        2
      ],
      [
        42,
        "4.2.1",
        "Enrollment/Screening Period",
        3
      ],
      [
        43,
        "Table 4",
        "Schedule of Screening Procedures",
        "4"
      ],
      [
        44,
        "4.2.2",
        "Treatment and Follow-up Periods",
        3
      ],
      [
        45,
        "Table 5",
        "Schedule of Treatment Period and Follow-up Period Study Procedures",
        "4"
      ],
      [
        46,
        "4.3",
        "Description of Study Procedures",
        2
      ],
      [
        47,
        "4.3.1",
        "Efficacy.",
        3
      ],
      [
        48,
        "4.3.1.1",
        "Lower Respiratory Tract Infection",
        4
      ],
      [
        49,
        "Table 6",
        "Criteria for Meeting the Protocol-defined Endpoint of Medically Attended RSV LRTI",
        "5"
      ],
      [
        50,
        "4.3.2",
        "Medical History and Physical Examination, Weight, and Vital Signs",
        3
      ],
      [
        51,
        "4.3.3",
        "Pharmacokinetics and Antidrug Antibody",
        3
      ],
      [
        52,
        "4.3.3.1",
        "Pharmacokinetic Evaluation",
        4
      ],
      [
        53,
        "4.3.3.2",
        "Antidrug Antibody Evaluation",
        4
      ],
      [
        54,
        "4.3.4",
        "Healthcare Resource Utilization",
        3
      ],
      [
        55,
        "4.3.5",
        "Skin Reactions",
        3
      ],
      [
        56,
        "4.4",
        "Study Suspension or Termination",
        2
      ],
      [
        57,
        "4.5",
        "Investigational Products",
        2
      ],
      [
        58,
        "4.5.1",
        "Identity of Investigational Products",
        3
      ],
      [
        59,
        "Table 7",
        "Identification of Investigational Products",
        "4"
      ],
      [
        60,
        "4.5.1.1",
        "Investigational Product Inspection",
        4
      ],
      [
        61,
        "4.5.1.2",
        "Dose Administration Steps",
        4
      ],
      [
        62,
        "4.5.1.3",
        "Treatment Administration",
        4
      ],
      [
        63,
        "4.5.1.4",
        "Monitoring of Dose Administration",
        4
      ],
      [
        64,
        "4.5.1.5",
        "Reporting Product Complaints",
        4
      ],
      [
        65,
        "4.5.2",
        "Additional Study Medications",
        3
      ],
      [
        66,
        "4.5.3",
        "Labeling",
        3
      ],
      [
        67,
        "4.5.4",
        "Storage",
        3
      ],
      [
        68,
        "4.5.5",
        "Treatment Compliance",
        3
      ],
      [
        69,
        "4.5.6",
        "Accountability",
        3
      ],
      [
        70,
        "4.6",
        "Treatment Assignment and Blinding",
        2
      ],
      [
        71,
        "4.6.1",
        "Methods for Assigning Treatment Groups",
        3
      ],
      [
        72,
        "4.6.2",
        "Methods to Ensure Blinding",
        3
      ],
      [
        73,
        "4.6.3",
        "Methods for Unblinding",
        3
      ],
      [
        74,
        "4.6.3.1",
        "Unblinding in the Event of a Medical Emergency",
        4
      ],
      [
        75,
        "4.7",
        "Restrictions During the Study and Concomitant Treatment(s)",
        2
      ],
      [
        76,
        "4.7.1",
        "Permitted Concomitant Medications",
        3
      ],
      [
        77,
        "4.7.2",
        "Prohibited Concomitant Medications",
        3
      ],
      [
        78,
        "4.8",
        "Statistical Evaluation",
        2
      ],
      [
        79,
        "4.8.1",
        "General Considerations",
        3
      ],
      [
        80,
        "4.8.2",
        "Sample Size",
        3
      ],
      [
        81,
        "4.8.3",
        "Efficacy",
        3
      ],
      [
        82,
        "4.8.3.1",
        "Primary Efficacy Analysis",
        4
      ],
      [
        83,
        "4.8.3.2",
        "Secondary Analyses of the Primary Endpoint",
        4
      ],
      [
        84,
        "4.8.3.3",
        "Supplementary Analyses of the Primary Endpoint",
        4
      ],
      [
        85,
        "4.8.3.4",
        "Secondary Efficacy Analyses",
        4
      ],
      [
        86,
        "4.8.4",
        "Safety",
        3
      ],
      [
        87,
        "4.8.5",
        "Analysis of Pharmacokinetics and Antidrug Antibody",
        3
      ],
      [
        88,
        "4.8.5.1",
        "Pharmacokinetic Analysis",
        4
      ],
      [
        89,
        "4.8.5.2",
        "Antidrug Antibody Analysis",
        4
      ],
      [
        90,
        "4.8.6",
        "Exploratory Analysis",
        3
      ],
      [
        91,
        "4.8.6.1",
        "Healthcare Resource Utilization",
        4
      ],
      [
        92,
        "4.8.6.2",
        "Monitoring RSV Resistance to Nirsevimab",
        4
      ],
      [
        93,
        "4.8.6.3",
        "RSV LRTI Occurring from Day 152 to Day 361",
        4
      ],
      [
        94,
        "4.8.7",
        "Data Monitoring Committee",
        3
      ],
      [
        95,
        "4.8.8",
        "Interim Analysis",
        3
      ]
    ]
  },
  {
    "source_file_section": "ASSESSMENT OF SAFETY",
    "source_heading_number": "5",
    "parent_heading_num_seq": [
      "5"
    ],
    "parent_sec_id_seq": [
      96
    ],
    "derived_heading_level": 1,
    "pt_from_ontology": [
      ""
    ],
    "medical_terms": [],
    "page": 9,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "2_section_metadata",
    "sec_id": 96,
    "child_secid_seq": [
      [
        96,
        "5",
        "ASSESSMENT OF SAFETY",
        1
      ],
      [
        97,
        "5.1",
        "Definition of Adverse Events",
        2
      ],
      [
        98,
        "5.2",
        "Definition of Serious Adverse Events",
        2
      ],
      [
        99,
        "5.3",
        "Definition of Adverse Events of Special Interest",
        2
      ],
      [
        100,
        "5.3.1",
        "Anaphylaxis and Other Serious Hypersensitivity Reactions Including",
        3
      ],
      [
        101,
        "5.3.2",
        "Thrombocytopenia",
        3
      ],
      [
        102,
        "5.4",
        "Definition of New Onset Chronic Disease",
        2
      ],
      [
        103,
        "5.5",
        "Recording of Adverse Events",
        2
      ],
      [
        104,
        "5.5.1",
        "Time Period for Collection of Adverse Events",
        3
      ],
      [
        105,
        "5.5.2",
        "Follow-up of Unresolved Adverse Events",
        3
      ],
      [
        106,
        "5.5.3",
        "Deaths",
        3
      ]
    ]
  },
  {
    "source_file_section": "Potential Hy’s Law and Hy’s Law",
    "source_heading_number": "",
    "parent_heading_num_seq": [
      ""
    ],
    "parent_sec_id_seq": [
      107
    ],
    "derived_heading_level": 1,
    "pt_from_ontology": [
      ""
    ],
    "medical_terms": [],
    "page": 7,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "2_section_metadata",
    "sec_id": 107,
    "child_secid_seq": [
      [
        107,
        "",
        "Potential Hy’s Law and Hy’s Law",
        1
      ],
      [
        108,
        "5.6",
        "Reporting of Serious Adverse Events",
        2
      ],
      [
        109,
        "5.7",
        "Other Events Requiring Immediate Reporting",
        2
      ],
      [
        110,
        "5.7.1",
        "Overdose",
        3
      ],
      [
        111,
        "5.7.2",
        "Medication Error",
        3
      ],
      [
        112,
        "5.7.3",
        "Adverse Events of Special Interest",
        3
      ],
      [
        113,
        "5.7.3.1",
        "Anaphylaxis and Other Serious Hypersensitivity Reactions Including",
        4
      ],
      [
        114,
        "5.7.3.2",
        "Thrombocytopenia",
        4
      ],
      [
        115,
        "5.7.4",
        "New Onset Chronic Disease",
        3
      ]
    ]
  },
  {
    "source_file_section": "STUDY AND DATA MANAGEMENT",
    "source_heading_number": "6",
    "parent_heading_num_seq": [
      "6"
    ],
    "parent_sec_id_seq": [
      116
    ],
    "derived_heading_level": 1,
    "pt_from_ontology": [
      ""
    ],
    "medical_terms": [],
    "page": 1,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "2_section_metadata",
    "sec_id": 116,
    "child_secid_seq": [
      [
        116,
        "6",
        "STUDY AND DATA MANAGEMENT",
        1
      ],
      [
        117,
        "6.1",
        "Training of Study Site Personnel",
        2
      ],
      [
        118,
        "6.2",
        "Monitoring of the Study",
        2
      ],
      [
        119,
        "6.2.1",
        "Source Data",
        3
      ],
      [
        120,
        "6.2.2",
        "Study Agreements",
        3
      ],
      [
        121,
        "6.2.3",
        "Archiving of Study Documents",
        3
      ],
      [
        122,
        "6.3",
        "Study Timetable and End of Study",
        2
      ],
      [
        123,
        "6.4",
        "Data Management",
        2
      ],
      [
        124,
        "6.5",
        "Study Physician Coverage",
        2
      ]
    ]
  },
  {
    "source_file_section": "ETHICAL AND REGULATORY REQUIREMENTS",
    "source_heading_number": "7",
    "parent_heading_num_seq": [
      "7"
    ],
    "parent_sec_id_seq": [
      125
    ],
    "derived_heading_level": 1,
    "pt_from_ontology": [
      ""
    ],
    "medical_terms": [],
    "page": 1,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "2_section_metadata",
    "sec_id": 125,
    "child_secid_seq": [
      [
        125,
        "7",
        "ETHICAL AND REGULATORY REQUIREMENTS",
        1
      ],
      [
        126,
        "7.1",
        "Subject Data Protection",
        2
      ],
      [
        127,
        "7.2",
        "Ethics and Regulatory Review",
        2
      ],
      [
        128,
        "7.3",
        "Informed Consent",
        2
      ],
      [
        129,
        "7.4",
        "Changes to the Protocol and Informed Consent Form",
        2
      ],
      [
        130,
        "7.5",
        "Audits and Inspections",
        2
      ]
    ]
  },
  {
    "source_file_section": "REFERENCES",
    "source_heading_number": "8",
    "parent_heading_num_seq": [
      "8"
    ],
    "parent_sec_id_seq": [
      131
    ],
    "derived_heading_level": 1,
    "pt_from_ontology": [
      ""
    ],
    "medical_terms": [],
    "page": 7,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "2_section_metadata",
    "sec_id": 131,
    "child_secid_seq": [
      [
        131,
        "8",
        "REFERENCES",
        1
      ]
    ]
  },
  {
    "source_file_section": "Appendix A Additional Safety Guidance",
    "source_heading_number": "",
    "parent_heading_num_seq": [
      ""
    ],
    "parent_sec_id_seq": [
      132
    ],
    "derived_heading_level": 1,
    "pt_from_ontology": [
      ""
    ],
    "medical_terms": [],
    "page": 1,
    "is_active": true,
    "aidocid": "ssr_cr1",
    "genre": "2_section_metadata",
    "sec_id": 132,
    "child_secid_seq": [
      [
        132,
        "",
        "Appendix A Additional Safety Guidance",
        1
      ]
    ]
  }
]